The partnership will enhance the already high level of expertise that Ricerca has in this field and will enable it to continue to deliver excellence within the fields of toxicology.
“Dr. Stadler is a well-respected expert, and her extensive experience is recognized internationally by both industry and regulatory professionals,” stated Ian Lennox, CEO of Ricerca. “This collaboration enables our clients to access the highest standard of advisory expertise and reinforces Ricerca's leadership in reproductive and juvenile toxicology.”
Once the compound is selected for drug development, Ricerca professionals help companies choose the best study parameters and protocol that best suit the study at hand. Ricerca’s expertise in conducting studies and developing the requisite data package and reports for IND submission can help ensure the success of potential candidates.
Ricerca Biosciences provides a full range of preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability.
About Ricerca Biosciences
Ricerca Biosciences, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds AAALAC certification.